ONCOLYTICS BIOTECH INC

ONCYNASDAQ

🏆 #3213 by market capEarnings Aug 14US Equity

$0.82▲ $0.02 (+2.14%)

🌙 After hours$0.82▲ 0.01%Regular close · extended-hours price shown

1h—

24h▲ 2.1%

7d▲ 2.3%

14d▲ 9.5%

30d▼ 10.6%

1y▼ 5.1%

🏦Market Cap

$82M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $0.81 – $0.83
52-Week Range: $0.73 – $1.51
Volume: $2.14B
Avg Volume: $2.72B
Shares Outstanding: 100.4M
Next Earnings: Oct 10, 2026

Fundamentals Snapshot

Annual Revenue: $7M
Last Q Revenue: $2M
P/E Ratio: -3.4
P/S Ratio: 0.0x
EPS (TTM): $-0.32
Dividend Yield: 0.00%

Why Investors Own ONCY

✓High-growth profile — revenue up +15.4% YoY with expanding US Equity exposure.
✓Healthy economics — 28% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$7M▲ +19.3% YoY

Gross Margin (TTM)

28.2%▲ +1.6% YoY

Operating Income (TTM)

$990,229▲ +19.3% YoY

Free Cash Flow (TTM)

$655,692▲ +19.3% YoY

About ONCOLYTICS BIOTECH INC

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

🦦